A composite index for determining the impact of oral ulcer activity in Behcet's disease and recurrent aphthous stomatitis

Journal of Oral Pathology and Medicine

Volumn 38, Issue 10, 2009, Pages 785-791

  Mumcu, G ^a   Sur, H ^a   Inanc, N ^b   Karacayli, U ^c   Cimilli, H ^b   Sisman, N ^a   Ergun, T ^b   Direskeneli, H ^b  

^a Faculty of Health Sciences   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Activity index; Behcet's disease; Oral ulcer; Recurrent aphthous stomatitis

Indexed keywords

COLCHICINE;

ADULT; APHTHOUS STOMATITIS; ARTICLE; BEHCET DISEASE; CLINICAL FEATURE; COMPARATIVE STUDY; COMPOSITE INDEX; CONTENT VALIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FUNCTIONAL STATUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PAIN; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; BEHCET SYNDROME; CASE-CONTROL STUDIES; COLCHICINE; CROSS-SECTIONAL STUDIES; DEGLUTITION DISORDERS; EATING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MASTICATION; ORAL ULCER; PAIN MEASUREMENT; PILOT PROJECTS; RECURRENCE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SPEECH DISORDERS; STOMATITIS, APHTHOUS; TASTE DISORDERS; TIME FACTORS; WOUND HEALING;

EID: 70350448615     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00803.x     Document Type: Article

References (27)

1. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet's disease activity index. Rheumatology 2004 43 : 73 8.
2. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999 38 : 728 733.
3. Müftüòlu AU, Yazici H, Yurdakul S, et al. Behçet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int Dermatol 1986 25 : 235 239.
4. International Study Group for Behcet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990 335 : 1078 1080.
5. International Society for Behçet's Disease. Disease measurement forms. http://www.behcet.ws, last accessed date 1/3/2009.
6. Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient's age on prevalence and severity of manifestations in BS. Ann Rheum Dis 1984 43 : 783 789.
7. Fresko I, Soy M, Hamuryudan V, et al. Genetic anticipation in Behçet's syndrome. Ann Rheum Dis 1998 57 : 45 8.
8. Mumcu G. Behçet's disease: a dentist's overview. Clin Exp Rheumatol 2008 26 (4 Suppl 50 S121 4.
9. Mumcu G, Ergun T, Inanc N, et al. Oral health is impaired in Behçet's disease and is associated with disease severity. Rheumatology (Oxford) 2004 43 : 1028 1033.
10. Mumcu G, Niazi S, Stewart J, et al. Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behcet's disease. J Oral Pathol Med 2009 38 : 406 409.
11. Mumcu G, Inanc N, Ergun T, et al. Oral health related quality of life is affected by disease activity in Behcet's disease. Oral Dis 2006 12 : 145 151.
12. Mumcu G, Hayran O, Ozalp DO, et al. The assessment of oral health related quality of life by factor analysis in patients with Behcet disease and recurrent apthous stomatitis. J Oral Pathol Med 2007 36 : 147 152.
13. Mumcu G, Ergun T, Elbir Y, et al. Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med 2005 34 : 13 6.
14. Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis. Br J Oral Maxillofac Surg 2008 46 : 198 206.
15. Krause I, Mader R, Sulkes J, et al. Behçet's disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol 2001 28 : 1033 1036.
16. McGrath C, Hegarty AM, Hodgson TA, Porter SR. Patient-centered outcome measures for oral mucosal disease are sensitive to treatment. Int J Oral Maxillofac Surg 2003 32 : 334 336.
17. Lyman HB. Test scores and what they mean: basic attributes of the test, 6th edn. Boston, MA : Allyn & Bacon, 1998.
18. Lee JH, Jung JY, Bang D. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease. J Eur Acad Dermatol Venereol 2008 22 : 590 595.
19. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D 2003 4 : 19 28.
20. Karacayli U, Mumcu G, Simsek I, et al. The close association between dental and periodontal treatments and oral ulcer course in Behcet's disease: a prospective clinical study. J Oral Pathol Med 2009 38 : 410 415.
21. Bacanli A, Yerebakan Dicle O, Parmaksizoglu B, Yilmaz E, Alpsoy E. Topical granulocyte colony-stimulating factor for the treatment of oral and genital ulcers of patients with Behçet's disease. J Eur Acad Dermatol Venereol 2006 20 : 931 935.
22. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneouos lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 128 : 443 450.
23. Rogers R. Recurrent apthous stomatitis in the diagnosis of Behçet's disease. Yonsei Med J 1997 6 : 370 379.
24. Krause I, Rosen Y, Kaplan I, et al. Recurrent aphthous stomatitis in behçet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med 1999 28 : 193 196.
25. Krause I, Yankevich A, Fraser A, et al. Prevalance and clinical aspects of Behçet's disease in north of Israel. Clin Rheumatol 2007 26 : 555 560.
26. Hatemi G, Silman A, Dang B, et al. EULAR recommendation for the management of Behçet's disease. Ann Rheum Dis 2008 67 : 1656 1662.
27. Almoznino G, Ben-Cherit E. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature. Clin Exp Rheumatol 2007 25 (Suppl. 45 S99 102.